Product name:Sunitinib malate
CAS: 341031-54-7
Molecular Formula: C22H27FN4O2.C4H6O5
Molecular Weight: 532.566
Product description:A new kind of oral targets more antitumor drugs, belong to multiple targets tyrosine kinase inhibitors, commodity name sutent (suntent), is developed by Pfizer (Pfizer) by the United States, with dual antitumor effect, is the only breakthrough in the treatment of advanced kidney cancer 2 years survival drugs in renal cell carcinoma and gastrointestinal stromal tumor therapy has the core status.By preventing tumor cells growth of blood and nutrients needed for treatment. Clinical trials showed that the drug could delay the growth speed of gastrointestinal stromal tumors, and can shrink the size of the renal cell cancer. Malic acid chougny for he was the first to selectively for multiple tyrosine kinase receptor of new targeted drugs, combined with the supply blood to the tumor cell suspension of resistance to blood vessel formation and direct attacks on the anti-tumor two mechanisms of tumor cells.